Evidence map›Paper›PMID 41764695›Full record

ArticleMolecular diversity2026

Ligand-based graph neural network, molecular dynamics and biological evaluation for identification of potential FGFR1 kinase inhibitors.

Tao Wu, Tao Wei, Junwei Zhu, Hongliang Zhong, Jie Ouyang, Yucan Wu, Wenfei He, Jianzhang Wu, Wulan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tao Wu *The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Tao Wei *Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, 325000, Zhejiang, China.
Junwei ZhuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Hongliang ZhongThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Jie OuyangSchool of Chinese Medicine, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Yucan WuZhejiang University-University of Illinois Urbana-Champaign Institute, Zhejiang University, Zhejiang, 314400, China.
Wenfei HeSchool of Chinese Medicine, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. wenfeihe@126.com.
Jianzhang WuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, 325000, Zhejiang, China. wjzwzmu@163.com.
Wulan LiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. lwlwzmu@163.com.

Funding

National Natural Science Foundation of China 81402839Research Initiation Project of the Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University KYQD20230901Science and Technology Department of National Administration of Traditional Chinese Medicine & Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-23032
6 · The paper itself

Abstract

Currently approved FGFR1 kinase inhibitors still suffer from several disadvantages, including significant toxicities and adverse effects. To identify promising FGFR1 inhibitors, we developed a ligand-based graph neural network (GNN) virtual screening model and conducted high-throughput screening of FGFR1 kinase inhibitors using this model. Compared with traditional models, our model reveals better performance (Accuracy of 0.9186, AUC of 0.964). The model was employed to conduct preliminary screening of a 14-million-compound library. Subsequently, multi-stage screening was performed, including two rounds of molecular docking and two stages of molecular dynamics simulations. This approach identified five compounds capable of forming stable hydrogen bond interactions with FGFR1 and strong binding free energy (between − 28.23 and − 34.24 kcal/mol), which exhibited adequate binding stability in 300 ns molecular dynamics simulation. Four of the compounds were then subjected to biological evaluation, which revealed that they exhibited varying degrees of inhibitory activity against FGFR1 kinase. Notably, two of these compounds demonstrated excellent inhibitory activity ([Formula: see text]M and 3.3 [Formula: see text]M, respectively). In summary, this study developed a high-throughput virtual screening model for FGFR1 kinase inhibitors based on graph neural networks, providing novel lead compounds for the research of FGFR1 kinase inhibitors.

Indexed as

Molecular Dynamics SimulationProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1Graph Neural NetworksHumansHydrogen BondingLigandsMolecular Docking SimulationFGFR1 protein, humanLigandsProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1Drug discoveryFibroblast growth factor receptor 1 inhibitorsGraph neural networkMolecular dynamicsVirtual screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.